Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer.
J Comp Eff Res. 2020 Dec;9(18):1301-1309. doi: 10.2217/cer-2020-0053. Epub 2020 Dec 16.
J Comp Eff Res. 2020.
PMID: 33325265